TransMedics Outlines Expansion Plan Amid U.S. Transplant Market Challenges

TransMedics (TMDX), a leader in organ preservation and transplantation technology, outlined its expansion plans at the 2026 Global Healthcare Conference, focusing on scaling its U.S. and international operations while addressing critical market inefficiencies. The company, with a market cap of $3.02 billion and a stock price of $87.71 (down ~44% from its 52-week high of $156), reaffirmed its 20%–25% year-over-year revenue growth target, reflecting a four-year CAGR of 86% and 2025 product and service revenues up 15% and 30%, respectively. With over $470 million in cash reserves and a gross profit margin of nearly 59%, the company operates 20 clinical hubs and 22 aircraft, supporting 140 pilots and 50 procurement surgeons. Its digital command center now manages over 35% of national transplant volume annually, and it has completed 5,000 transplants in 2025, aiming for 10,000 by 2028 and 20,000 by 2030.